RG 6146

Drug Profile

RG 6146

Alternative Names: RG6146; RO 6870810; TEN 010

Latest Information Update: 27 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tensha Therapeutics
  • Developer Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 26 Jun 2017 Phase-I clinical trials in Multiple myeloma (Late-stage disease, Combination therapy, In adults, In the elderly, Second-line therapy or greater) in USA, Australia (SC) (NCT03068351)
  • 26 Jun 2017 Phase-I clinical trials in Multiple myeloma (Monotherapy, Second-line therapy or greater, Late-stage disease, In adults, In the elderly) in Australia, USA (SC) (NCT03068351)
  • 01 Oct 2014 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) and Myelodysplastic syndromes (Second-line therapy or greater) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top